Reyvow™ (lasmiditan) C-V: A First-in-Class Acute Treatment for Migraine Is Now Available
January 31, 2020
Lilly is proud to announce that Reyvow™ (lasmiditan) C-V, 50 mg and 100 mg tablets, an oral medication for the acute treatment of migraine, with or without aura in adults, is now available by prescription. Reyvow is the first FDA-approved migraine medicine in a new class of acute treatment in over two decades. It is also the first and only ditan, a 5-HT1F receptor agonist, approved to treat migraine attacks when they occur.
Learn more about migraine and how Reyvow can make a difference for patients:
Read the press release
View Reyvow’s key facts
Learn more about migraine
Read a letter from the Lilly Bio-Medicines president about our commitment to advancing the treatment for migraine
IMPORTANT SAFETY INFORMATION FOR REYVOW
WARNINGS AND PRECAUTIONS
Reyvow may cause significant driving impairment. In a driving study, administration of single 50 mg, 100 mg, or 200 mg doses of Reyvow significantly impaired subjects’ ability to drive. Additionally, more sleepiness was reported at 8 hours following a single dose of Reyvow compared to placebo. Advise patients not to engage in potentially hazardous activities requiring complete mental alertness, such as driving a motor vehicle or operating machinery, for at least 8 hours after each dose of Reyvow. Patients who cannot follow this advice should not take Reyvow. Prescribers and patients should be aware that patients may not be able to assess their own driving competence and the degree of impairment caused by Reyvow.
Central Nervous System Depression
Reyvow may cause central nervous system (CNS) depression, including dizziness and sedation. Because of the potential for Reyvow to cause sedation, other cognitive and/or neuropsychiatric adverse reactions, and driving impairment, Reyvow should be used with caution if used in combination with alcohol or other CNS depressants. Patients should be warned against driving and other activities requiring complete mental alertness for at least 8 hours after Reyvow is taken.
In clinical trials, reactions consistent with serotonin syndrome were reported in patients treated with Reyvow who were not taking any other drugs associated with serotonin syndrome. Serotonin syndrome may also occur with Reyvow during coadministration with serotonergic drugs [e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and monoamine oxidase (MAO) inhibitors]. Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, coma), autonomic instability (e.g., tachycardia, labile blood pressure, hyperthermia), neuromuscular signs (e.g., hyperreflexia, incoordination), and/or gastrointestinal signs and symptoms (e.g., nausea, vomiting, diarrhea). The onset of symptoms usually occurs within minutes to hours of receiving a new or a greater dose of a serotonergic medication. Discontinue Reyvow if serotonin syndrome is suspected.
Medication Overuse Headache
Overuse of acute migraine drugs (e.g., ergotamines, triptans, opioids, or a combination of drugs for 10 or more days per month) may lead to exacerbation of headache (i.e., medication overuse headache). Medication overuse headache may present as migraine-like daily headaches or as a marked increase in frequency of migraine attacks. Detoxification of patients including withdrawal of the overused drugs and treatment of withdrawal symptoms (which often includes a transient worsening of headache) may be necessary.
The most common adverse reactions associated with Reyvow (≥2% and greater than placebo in clinical studies) were dizziness, fatigue, paresthesia, sedation, nausea and/or vomiting, and muscle weakness.
DRUG ABUSE AND DEPENDENCE
Reyvow contains lasmiditan, a Schedule V controlled substance
In a human abuse potential study in recreational poly-drug users (n=58), single oral therapeutic doses (100 mg and 200 mg) and a supratherapeutic dose (400 mg) of Reyvow were compared to alprazolam (2 mg) (C-IV) and placebo. With all doses of Reyvow, subjects reported statistically significantly higher “drug liking” scores than placebo, indicating that Reyvow has abuse potential. Subjects who received Reyvow reported statistically significantly lower “drug liking” scores than alprazolam. Euphoric mood occurred to a similar extent with Reyvow 200 mg, Reyvow 400 mg, and alprazolam 2 mg (43-49%). A feeling of relaxation was noted in more subjects on alprazolam (22.6%) than with any dose of Reyvow (7-11%). Phase 2 and 3 studies indicate that, at therapeutic doses, Reyvow produced adverse events of euphoria and hallucinations to a greater extent than placebo. However, these events occur at a low frequency (about 1% of patients). Evaluate patients for risk of drug abuse and observe them for signs of lasmiditan misuse or abuse.
Physical withdrawal was not observed in healthy subjects following abrupt cessation after 7 daily doses of lasmiditan 200 mg or 400 mg.
LM HCP ISI 11JAN2020
Reyvow™ is a trademark owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates. PP-LM-US-0171 01/2020 ©Lilly USA, LLC 2020. All rights reserved.